tafluprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 4229 209860-87-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tafluprost
  • tafluprost ophthalmic solution
  • zioptan
  • taflotan
  • tapros
a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow
  • Molecular weight: 452.54
  • Formula: C25H34F2O5
  • CLOGP: 4.26
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 75.99
  • ALOGS: -4.93
  • ROTB: 13

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 10, 2012 FDA OAK PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ocular hyperaemia 227.61 37.09 56 871 25088 63463007
Eye irritation 159.10 37.09 41 886 21930 63466165
Eye pain 146.01 37.09 42 885 33812 63454283
Eye pruritus 116.53 37.09 31 896 18640 63469455
Eye swelling 61.51 37.09 20 907 23898 63464197
Intraocular pressure increased 42.17 37.09 11 916 6067 63482028

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ocular hyperaemia 87.01 57.93 21 366 11431 34945113
Eye irritation 68.46 57.93 16 371 7545 34948999

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ocular hyperaemia 152.53 32.39 41 1022 28165 79715160
Eye pain 89.59 32.39 29 1034 37549 79705776
Eye irritation 70.47 32.39 21 1042 20660 79722665
Eye pruritus 57.74 32.39 18 1045 20552 79722773
Pemphigoid 41.28 32.39 13 1050 15302 79728023
Atrioventricular block second degree 41.14 32.39 11 1052 7301 79736024
Cardiovascular insufficiency 34.51 32.39 8 1055 2973 79740352
Intraocular pressure increased 34.17 32.39 10 1053 9195 79734130

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01EE05 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Prostaglandin analogues
FDA CS M0017805 Prostaglandins
FDA MoA N0000000106 Prostaglandin Receptor Agonists
FDA PE N0000009526 Increased Prostaglandin Activity
FDA EPC N0000175454 Prostaglandin Analog
CHEBI has role CHEBI:66900 prostaglandin receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Open-angle glaucoma indication 84494001 DOID:1067




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.0015% ZIOPTAN THEA PHARMA N202514 Feb. 10, 2012 RX SOLUTION/DROPS OPHTHALMIC 10864159 May 28, 2029 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin F2-alpha receptor GPCR AGONIST CHEMBL CHEMBL

External reference:

IDSource
4031331 VUID
N0000184322 NUI
D06274 KEGG_DRUG
4031331 VANDF
C1451502 UMLSCUI
CHEBI:66899 CHEBI
CHEMBL1963683 ChEMBL_ID
DB08819 DRUGBANK_ID
C485333 MESH_SUPPLEMENTAL_RECORD_UI
7451 IUPHAR_LIGAND_ID
8374 INN_ID
1O6WQ6T7G3 UNII
9868491 PUBCHEM_CID
1244607 RXNORM
187543 MMSL
26696 MMSL
013244 NDDF
699181001 SNOMEDCT_US
704470009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tafluprost HUMAN PRESCRIPTION DRUG LABEL 1 0781-6184 SOLUTION/ DROPS 0.00 mg OPHTHALMIC ANDA 24 sections
ZIOPTAN HUMAN PRESCRIPTION DRUG LABEL 1 17478-609 SOLUTION/ DROPS 0.00 mg OPHTHALMIC NDA 25 sections
ZIOPTAN HUMAN PRESCRIPTION DRUG LABEL 1 17478-609 SOLUTION/ DROPS 0.00 mg OPHTHALMIC NDA 25 sections
ZIOPTAN HUMAN PRESCRIPTION DRUG LABEL 1 17478-609 SOLUTION/ DROPS 0.00 mg OPHTHALMIC NDA 25 sections
tafluprost HUMAN PRESCRIPTION DRUG LABEL 1 42571-264 SOLUTION/ DROPS 0.00 mg OPHTHALMIC ANDA 23 sections
Tafluprost HUMAN PRESCRIPTION DRUG LABEL 1 65302-062 SOLUTION 0.00 mg OPHTHALMIC ANDA 2 sections
Tafluprost Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 66993-429 SOLUTION/ DROPS 0.00 mg OPHTHALMIC NDA authorized generic 25 sections
ZIOPTAN HUMAN PRESCRIPTION DRUG LABEL 1 82584-609 SOLUTION/ DROPS 0.02 mg OPHTHALMIC NDA 28 sections